+ 86 (1360) 2568149 info@phcoker.com

Paheʻeʻo Avanafil (330784-47-9)

Hoʻohana ʻia ka paukū Avanafil e mālama i nā kāne i loaʻa ka hana (ka mea i kapa ʻia ʻo ka pelekikena pelekane). Na Avanafil i hui pū me …… ..


Kūlana: I ka Production Production
Mokuna: 25kg / Drum
nona iho: 1290kg / ka mahina

Description

ʻO ka'ōmoleʻo Avanafil (330784-47-9)

ʻO ka uila Avanafil (330784-47-9) Hōʻike

ʻO ka pauku Raw Avanafil kahi PDE5 inhibitor i ʻae ʻia no ka neʻe ʻana (ED: impotence; hiki ʻole ke loaʻa a mālama paha i kahi neʻe ʻana i nā kāne). Ka hana ʻana ʻo Av Avanafil pauka ma ke kāohi ʻana i kahi enzyme phosphodiesterase type 5 e loaʻa ana i nā ʻano kino o ke kino, akā nui ka mea i loko o ka corpus cavernosum penis, a me ka retina. Hana ia ma o ka hoʻonui ʻana i ke kahe koko i ka penis i ka wā o ka hoʻoulu ʻana. ʻO nā lāʻau'ē aʻe e like me ka sildenafil, tadalafil a me ka vardenafil. ʻO ka pōmaikaʻi o ka paukū Raw Avanafil, ʻo ia ka wikiwiki o ka hoʻomaka ʻana o ka hana i hoʻohālikelike ʻia me nā mea paʻa PDE5. Paki koke ʻia ia mea, a hiki i ka lōʻihi o ka maka ma 30-45 mau minuke.A ʻelua hapakolu o nā poʻe i komo i ka hana moe kolohe i loko o nā minuke 15.

Paheʻeʻo Avanafil (330784-47-9) Snāʻike

Product Name Pālaʻiʻo Avanafil
Hawaiian Name 330784-47-9;STENDRA; (s)-4-((3-Chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide; TA 1790; TA-1790
Brand Name ʻO Stendra lāuaʻo Spedra
Kōpana Drug PDE5 hoʻolālā
Kāleka CAS 330784-47-9
InChIKey WEAJZXNPAWBCOA-INIZCTEOSA-N
hakakino F'Oula C23H26ClN7O3
hakakino Wʻewalu 483.95
Monoisotopic Mass 483.179 g / mole
Hoʻolaha Pʻo kaʻaila 150-152 ° C
Fkū hou Pʻo kaʻaila ʻAʻoheʻikepili i loaʻa
ʻO ka Halifa-Ola Mean mean-half-life = 5.36 - 10.66 hola
Keʻano ʻO ka pauma
Solakino DMSO, Methanol
Ska hoʻokele Tka mahana E kūʻai i 4 ° C
noi ʻO kahi inhibitor phosphodiesterase (PDE5), i hoʻohana ʻia e mālama i ka hana holo.

ʻO ka uila Avanafil (330784-47-9) Hōʻike

Hoʻohana ʻia ʻo Avanafil e mālama i ka hana disfunction (ED: impotence; hiki ʻole ke kiʻi a mālama paha i kahi kikowaena kāne). ʻO ka pauku Avanafil i loko o kahi papa o nā lāʻau lapaʻau i kapa ʻia nā inhibitors phosphodiesterase (PDE). Hana ia ma o ka hoʻonui ʻana i ke kahe koko i ka penis i ka wā o ka hoʻoulu ʻana. Hiki i kēia ke kahe koko ke kumu e kūpaʻa ai. ʻAʻole hōʻoluʻolu ka Avanafil pau i ka hana disfunction a hoʻonui paha i ka makemake moekolohe. ʻAʻole i pale aku ʻo Avanafil i ka hapai a i ʻole ka pālahalaha ʻia o nā maʻi like ʻole e like me ke kanaka immunodeficiency virus (HIV).

ʻO kaʻeha Avanafil (330784-47-9) Mechanism of Action

ʻO Avanafil kahi mea hoʻopihapiha o ka phosphodiesterase 5 (PDE5) enanthuni inhibitor i hoʻohana ʻia no ka mālama ʻana i ka hana maʻi maʻi ma muli o ka maʻi maʻi, nā makahiki hoʻonaninani a ka maʻi oxidative a i ʻole nā ​​hoʻopili. Hāʻalo ʻo Avanafil i ka cGMP kikoʻī ʻano phodiodiasease 5 (PDE5) nona ke kuleana o ka hōʻino o cGMP i ka cavernosum corpus e kū ana a puni ka penis. Hoʻokumu ʻia ka penile i ka wā hoʻokalakupua ʻia e ka piʻi ʻana o ke kahe penile i hua ʻia ma muli o ka hoʻomaha ʻana o ka penile arteri a me ka pīpī polipus cavernosal. Hoʻolaha ʻia kēia pane ma ka hoʻokuʻu ʻana o ka nitric oxide (NO) mai nā nū o nā nerve a me nā ʻāpana endothelial, ka mea e hoʻoulu ai i ke kāpili ʻana o ka cGMP i loko o nā puʻuwai ma nā lehelehe. Hoʻokomo ʻo Cyclic GMP i ka hoʻomaha mālie o ka naʻau a hoʻonui i ke kahe koko i loko o ka ca corosus corpus. ʻO ka pale ʻana i ka type o ka phosphodiesterase 5 (PDE5) e ka avanafil e hoʻonui i ka hana me ka hoʻonui ʻana i ka nui o cGMP.

Ke hoʻohanaʻiaʻana o ka paonaʻo Avanafil (330784-47-9)

Hoʻohana ʻia ka paukū Avanafil e mālama i nā kāne i loaʻa ka hana (ka mea i kapa ʻia ʻo ka pelekikena pelekane).

Hōʻikeʻia ka paona o Avanafil (330784-47-9) Hana

No ka hapanui o nā kānaka,ʻo ka laha hoʻomaka i ka paona avanafil ka 100 mg i kēlā lā i kēia lā e pili ana i nā minuke 30 ma mua o ka hana maʻamau. Ma muli o ke kūpono o ka pane a iʻole nā ​​hopenaʻaoʻao, hiki ke hoʻonuiʻia ka hōʻailona i ka 200 mg a i emi iho i ka 50 mg i ka lā. ʻO nā kānaka e lawe nei i nā lāʻau e hoʻonui i ke koko o avanafil,ʻaʻole lākou eʻoi aku ma mua o ka nui o ka nui o ka 50 mg i nā hola 24 (Eʻike i nā pilikino).

Nā hua o kaʻepa o'Anaanafil (330784-47-9)

E haʻalele i ka avanafil ae kāhea i kāu kauka inā loaʻa iāʻoe:

▪ nā loli o kaʻike, ka nalowale o kaʻike pōʻino;

▪ ke kani nei i loko o kou mau pepeiao, aiʻole ka loli pepeiao hoʻoloheʻole;

▪ kaʻeha, ka pehuʻana, ka mahana, a me kaʻulaʻula i loko o hoʻokahi aʻelua paha mau wāwae;

▪ ka pōkole o ka hanu, kūpikipiki i loko o kou lima a mau wāwae paha;

▪ he manaʻo hoʻokele, e like paha me kou hikiʻana i waho; aiʻole

▪ ka peni hale e hoʻopiʻi a hoʻomaha paha i nā hola 4 a lōʻihi paha.

Hiki ke komo i nā hopenaʻaoʻao maʻamau:

▪ i ke poʻo;

▪ hoʻohuiʻia (kahi mahana,ʻulaʻula, aʻoluʻolu paha);

▪ nā hōʻailona maʻamau e like me ka ihu iʻole ka ihu, ka puʻu'ā'ī; aiʻole

▪ kaʻeha hou.

NA HALO A E HOOLAHA:

E kūʻai ʻia ana kēia ʻano mea no ka noiʻi noiʻi wale nō. Wahi a ke kūʻai aku. ʻAʻole no ka loiloi kanaka, ʻaʻole lāʻau lapaʻau, manu hoʻāno, a i ʻole e kōkua ʻia nā mea hale.


Nāʻike & nā hua'ōlelo huahana

Nā nīnau 9 e nīnau iāʻoe iho ma mua o ka lawe 'ana iā Avanafil

E hoʻomaopopo '

  1. ʻO Ryan M Burke, ʻO Jeffery D Evans, Avanafil no ka mālamaʻana i nā hana maʻi: e nānā ana i kona pono, ʻo Vasc Health Health Management. 2012; 8: 517 – 523.
  2. DeRogatis LR, Burnett AL. ʻO ka maʻi'ōpilikia o ka moe kolohe. J Sex Med. 2008; 5: 289-300.
  3. Zhao C, Kim S, Yan D, et al. Ka maikaʻi a me ka palekana o ka avanafil no ka mālamaʻana i nā hana disfunction: nā hopena o kahi hoʻokolohua multicentre, randomized, double-blind, hoʻokola-control trial. BJU Int. 2012 Mar 27;

ʻO Shangke Chemical he polokalamu kelehana kiʻekiʻe e kū nei i nā mea hana hana hoʻopihamaha hana (APIs). No ka mālamaʻana i ka maikaʻi i ka manawa o ka hanaʻana, kahi nui o nāʻoihana akamai, nā mea hana papa hana mua a me nā hale liʻiliʻi i nā kumu nui.

Kāhea iā mā˚ou